ArticleJCO precision oncology2026
Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposePrecision therapies have improved outcomes in pancreatic ductal adenocarcinoma (PDAC) and highlight the utility of germline genetic testing (GGT) in clinical decision making. Here, we investigate the association of GGT of individuals diagnosed with PDAC over time to identify changes in testing patterns and the relationship of testing with clinicopathologic parameters and overall survival (OS).
methodsThe frequency of GGT of 979 patients with PDAC treated at the Roswell Park Comprehensive Cancer Center (RPCCC) between 2017 and 2024 was determined. Factors associated with performing testing and having a germline pathogenic variant (GPV) were assessed. OS and the impact of precision treatment were evaluated.
resultsPatients with PDAC being treated at RPCCC that had GGT increased from 16.5% in 2017 to 57.6% in 2024. Patients with testing had improved OS compared with patients who did not (HR, 0.46). Individuals of older age, without a personal history of other cancers, without a family history of pancreatic cancer, with advanced disease, and with poorly differentiated tumors were less likely to have testing performed. Individuals with a personal history of other cancers were more likely to have a GPV. Of the 425 patients diagnosed with PDAC that had testing, 58 (13.6%) had a GPV detected. Of patients with testing, 12 had actionable mutations in
conclusionGGT prevalence has increased at RPCCC and informed treatment decisions. Universal point-of-care testing is being implemented with the goal of completing testing for all patients with PDAC seen at RPCCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.